Literature DB >> 1557981

Exfoliation syndrome and heparin surface modified intraocular lenses.

C Zetterström1, A Lundvall, G Olivestedt.   

Abstract

Either heparin surface modified (HSM) or regular polymethyl methacrylate (PMMA) intraocular lenses (IOLs) were implanted after extracapsular cataract extraction in 40 human eyes with exfoliation syndrome in a double-masked, randomized study. The patients were investigated preoperatively, and then 1 day, 1 week, 3, 6 and 12 months postoperatively. In eyes implanted with the HSM IOL, 26% had a fibrinoid reaction anterior to the IOL, while this complication was found in 50% of eyes implanted with the regular IOL. Pigment and cell deposits were more frequent on the regular IOLs than on the HSM lenses postoperatively. Posterior synechia formation between the iris and the implant or lens capsule was more common in the eyes with regular IOL compared to HSM IOL. No difference in visual acuity between the two groups was found either before or after surgery. The results suggest that in eyes with exfoliation syndrome, a heparin surface modified IOL reduces clinical complications associated with cataract surgery.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1557981     DOI: 10.1111/j.1755-3768.1992.tb02097.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  3 in total

1.  F-heparin modified intraocular lenses in Rhesus monkeys.

Authors:  Gui-Qin Wang; Han-Qing Gu; Jia-Qin Yuan; Hui-Min Sun; Yan-Shan Xu
Journal:  Int J Ophthalmol       Date:  2010-06-18       Impact factor: 1.779

2.  Visual outcome after phacoemulsification and IOL implantation in diabetic patients.

Authors:  A Zaczek; G Olivestedt; C Zetterström
Journal:  Br J Ophthalmol       Date:  1999-09       Impact factor: 4.638

3.  Hydrophobic acrylic versus heparin surface-modified polymethylmethacrylate intraocular lens: a biocompatibility study.

Authors:  Daniele Tognetto; Lisa Toto; Daniela Minutola; Enzo Ballone; Marta Di Nicola; Rocco Di Mascio; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-07-17       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.